Introduction Pedal onychomycosis is common, and its treatment entails debridement combined with topical and/or oral antifungal medication. Methods In this study, 69 participants were randomly allocated to either active (31 [44.93%]) or placebo (38 [55.07%]) topical solution. The primary outcome was mycological cure, and secondary outcomes included visible nail plate involvement and toenail-related quality of life. Results After a minimum duration of follow-up of 7 months and a maximum of 9 months, participants in the active solution group experienced statistically significantly greater mycological cure (1 [2.63%] placebo versus 17 [54.84%] active, p < 0.0001) and clinical cure (2 [5.56%] placebo versus 21 [70%] active, p < 0.0001), including 47.62% of which showed complete clearance of visible nail plate involvement with no residual gross nail plate dystrophy and improved toenail-related quality of life, including less symptom bothersomeness (p < 0.0344), less overall toenail problems (p < 0.0315), and greater satisfaction with treatment (p < 0.0195) as early as the 3-month follow-up visit. In addition, the active solution group experienced less frequent symptoms (p = 0.0046 at 9 months) and symptom bothersomeness (p = 0.0002 at 7 months, < 0.0001 at 9 months), less difficulty caring for toenails and better toenail appearance (p = 0.0250 at 7 months, p= 0.007 at 9 months), improved physical activity and less toenail pain (p = 0.0208 at 7 months, p = 0.003 at 9 months), less overall toenail problems (p = 0.0002 at 7 months, p = 0.0006 at 9 months), and greater treatment satisfaction (p = 0.0003 at 7 months, p = 0.0015 at 9 months). Conclusions Participants with pedal onychomycosis that were randomized to the active topical solution showed statistically significantly greater mycological and clinical cures, as well as improved quality of life, in comparison with those allocated to the placebo topical solution. Trial Registration ISRCTN Protocol no. 77852934.
Background: We present a retrospective radiographic analysis showcasing the ability to correct hallux valgus using the Lapidus arthrodesis without focused frontal plane rotation of the first metatarsal. Methods: A total of 33 feet in 30 patients who had undergone Lapidus arthrodesis for the treatment of hallux abducto valgus deformity from 1 August 2015 to 31 December 2020 were identified. The median age of the cohort was 55.4 years (range, 33–78 years), 23 were female (76.7%), three (10%) underwent bilateral Lapidus arthrodesis, and the median duration of follow-up was 15.9 months (range, 5–72 months). Results: The median (minimum, maximum) preoperative first intermetatarsal angle was 16° (13°, 28°), and at final follow-up it was 5° (0°, 6°) (p < 0.001). The median (minimum, maximum) preoperative hallux abductus angle was 37° (26°, 51°), and at final follow-up it was 8.5° (0°, 22.5°) (p < 0.001). The median (minimum, maximum) preoperative tibial sesamoid position was 6 (4, 7), and at final follow-up it was 3 (2, 5) (p = 0.001). Conclusions: We found the radiographic first metatarsal lateral round sign to be ambiguous. Qualitative comparison of the results of this investigation with prior studies describing outcomes following Lapidus arthrodesis with focused frontal plane rotation of the first metatarsal suggests that similar outcomes can be achieved without employment of a decisive frontal plane rotation of the first metatarsal. Our findings lead us to believe that correction of substantial hallux abducto valgus deformities can be accomplished using the Lapidus procedure combined with lateral release of the first metatarsophalangeal joint without focused derotation of the first metatarsal.